ALL Multiplex Panel

Function

The ALL (Acute Lymphoblastic Leukemia) Multiplex Panel is a specialized molecular diagnostic tool used to identify specific genetic rearrangements and chromosomal translocations within leukemic cells. By utilizing technologies like Multiplex PCR or Next-Generation Sequencing (NGS), this panel screens for hallmark abnormalities such as BCR-ABL1 (Philadelphia chromosome), ETV6-RUNX1, TCF3-PBX1, and MLL (KMT2A) rearrangements. These genetic markers are the primary drivers of leukemogenesis, influencing how lymphocyte precursors proliferate uncontrollably.

Why it is Ordered

This panel is standard protocol following a preliminary diagnosis of ALL via morphology and flow cytometry. It is ordered to:

• Risk Stratification: Determine if the leukemia is low-risk or high-risk.
• Targeted Therapy: Identify patients who will benefit from specific inhibitors (e.g., Tyrosine Kinase Inhibitors for BCR-ABL1 positive cases).
• Prognostication: Certain mutations, like ETV6-RUNX1, generally suggest a better prognosis in pediatric populations, whereas MLL rearrangements often indicate a more aggressive course.

Associated Conditions

The primary condition associated with this test is Acute Lymphoblastic Leukemia, the most common childhood cancer. However, it is also utilized in adult ALL cases. Results are used in conjunction with Minimal Residual Disease (MRD) monitoring to track the effectiveness of chemotherapy or stem cell transplants. Understanding the genetic architecture of the tumor allows oncologists to move away from 'one-size-fits-all' treatments toward precision medicine.